Kisqali Femara Co-Pack Interactions
There are 760 drugs known to interact with Kisqali Femara Co-Pack (letrozole/ribociclib), along with 8 disease interactions, and 3 alcohol/food interactions. Of the total drug interactions, 329 are major, 415 are moderate, and 16 are minor.
- View all 760 medications that may interact with Kisqali Femara Co-Pack
- View Kisqali Femara Co-Pack alcohol/food interactions (3)
- View Kisqali Femara Co-Pack disease interactions (8)
Most frequently checked interactions
View interaction reports for Kisqali Femara Co-Pack (letrozole / ribociclib) and the medicines listed below.
- acetaminophen / hydrocodone
- acetazolamide
- Activase (alteplase)
- Adriamycin (doxorubicin)
- alendronate
- Aleve (naproxen)
- alprazolam
- amoxicillin / clavulanate
- anastrozole
- atropine
- baclofen
- Bactroban (mupirocin topical)
- Benadryl (diphenhydramine)
- biotin
- calcium citrate
- calcium / vitamin d
- capecitabine
- cefdinir
- cephalexin
- Cinvanti (aprepitant)
- cisplatin
- Citracal Slow Release 1200 (calcium / vitamin d)
- Eliquis (apixaban)
- gabapentin
- omeprazole
- ondansetron
- promethazine
- venlafaxine
- Vitamin B12 (cyanocobalamin)
- Vitamin D3 (cholecalciferol)
Kisqali Femara Co-Pack alcohol/food interactions
There are 3 alcohol/food interactions with Kisqali Femara Co-Pack (letrozole / ribociclib).
Kisqali Femara Co-Pack disease interactions
There are 8 disease interactions with Kisqali Femara Co-Pack (letrozole / ribociclib) which include:
- liver disease
- cholesterol
- osteoporosis
- cutaneous toxicity
- hepatic impairment
- lung toxicity
- QT prolongation
- renal impairment
Report options
More about Kisqali Femara Co-Pack (letrozole / ribociclib)
- Kisqali Femara Co-Pack consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Drug class: antineoplastic combinations
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.